Corporate PresentationMarch 2015

Clinical Problems

• Initial Laparoscopic Access using a Veress needle has not changed in 30 years

• Complications rates are frequent and very expensive

• Time to insufflation!

Opportunity

• Simple innovation to allow safe and fast access to abdomen

• 15 million Laparoscopic procedures using Veress needle every year (extrapolated from available market data).

• Growing 8.3% per annum• Distributor friendly, single use device

Solution – ‘LapDome’• Clinical superiority

• Improves current standard of care • Improves patient safety

• Improved insufflation rates

• Reduced operating theatre budgets

• Reducing potential complications rates

Narvitas Medical Devices • Develop, patent, manufacture and sell proprietary medical

devices• 3 Initial Platforms, each leveraging the core technology• Class 1 - Large market segment – High Volume procedures

Laparoscopic Epidural Anesthesia Med Surg

15 mil procedures worldwide

130 mil births In dwelling catheter collection

EpiDome Jaws

Management Team

Glenn Foley Co-Founder & Dire CEO

AVE – Medtronic -

Precision Vascular

Daragh Sharkey Co-Founder & Director Sales

Mkt and Bus Dev

Aerogen, Altana, Trojan Med

Arthur Malvett Co-Founder & Director

Chief Operating Officer Life

Care Medical, Midland Bank

Medical Advisory Board

• Dr. Aidan Sharkey – Consultant Anesthetist UCHG – Specialty OBGYN

• Dr. Una Conway– Consultant OBGYN – Specialty in Laparoscopic Surgery

• Dr. Michael O’Dowd– Retired Consultant OBGYN – Pioneered Laparoscopic Surgery in UK / Ireland Author of 3

medical texts and numerous research papers

Advisors• Mr. Jerome Nathan

– Former CFO Centellax Corp, LLB University Paris, ACCA University Paris• Mr. Alan Crean

– CEO Poly Pico Medical, CEO Pointec Medical, Director Creganna

Professional Advisors

€452kSubscribed

€298kOpen

€2.3mValuation

Intellectual PropertyLaparoscopic SurgeryNational Phase Patent Application Number Patent Publication Number

US 13/640,015 US2013-0197315A1

Europe 10849757.9 EP2558006A1

Japan P2013-504347 P2013-523370A

Australia 2010351314 AU2010351314A1

South Korea 10-2012-7029658 10-20-130076816

UK GB1408740.7

Epidural AnesthesiaUK GB1409553.3

Distributor Strategy - EMEA

• UK, Ireland, Benelux Q2 – key hospitals and doctors identified

• Key distributors identified – specific expertise in GYN medical devices

• Clinical Backup

• Enterprise Ireland support and back up – key meetings, distributor selection

• Strategic focus on UAE / Saudi Arabia

Distributor Strategy - USA• US Laparoscopic Surgery Veress based procedure volume: 6,000,000 procedures

Surgical Principals Inc Active Medical EA Medical AMSCCS Surgical Adler InstrumentsMediflex USA

Support Programs• Europe/ME referral centers• White papers• Registry• Published papers• Economic Impact analysis

Product Pipeline and TimingDevice Class CE FDA JMOH

I CQI 2015 CQ4 2015 CQI 2016

2A Kits inc Veress CQ4 2015 CQ2 2016 CQ4 2016

EpiDome

CQ3 2015

CQ4 2015

CQI 2016

CQ1 2016

CQ1 2016

CQ3 2016

CQ2 2016

CQ2 2016

CQ4 2016

Financial Forecast

FY2015* FY2016** FY2017***

Sales Revenue €0 €1,585 €9,721

CGS €0 €287 €2,149

GP €0 €1,261 €7,419

OPEX €-232 €459 €1,116

EBITDA €-238 €802 (52%) €6,375 (66%)

* Europe** Europe +US + Latin America*** Europe +US + Latin America + Japan

Liquidity and Exit